Project Grant R13AR088378
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Cincinnati Children's Hospital Medical Center $510,175 on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms of skeletal muscle cell fusion. The research integrates biochemical, cellular, and genetic strategies to define the lipid pathways that enable myomaker-dependent lipid remodeling in myoblasts and establish the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $614,390 to the University of Georgia Research Foundation on May 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms of human myogenesis, specifically the role of the CHAMP1 gene in muscle development and CHAMP1 syndrome. The research focuses on myoblast fusion, an essential process for muscle development and regeneration. Prior...
- The National Cancer Institute awarded $112,000 to the Federation of American Societies for Experimental Biology (FASEB) under the Cancer Cause and Prevention Research program (CFDA 93.393) to support the 2025 FASEB Conference on "Mobile DNA: Mechanisms and Health Impact." The conference, scheduled for performance in Maryland from July 15, 2025 through June 30, 2026, will bring together transposon element (TE) researchers and aging scientists to examine the role of mobile DNA in somatic...
- The National Institute of Child Health and Human Development awarded University of Massachusetts Medical School $460,625 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop humanized muscle xenograft models for optimizing and assessing genome editing therapeutics targeting limb-girdle muscular dystrophy R9 (LGMDR9). The project delivers two specific research aims. Aim 1 optimizes prime editing correction of the FKRP L276I mutation in...
- The National Science Foundation awarded a $150,000 Project Grant to the University of California, San Diego under the Mathematical and Physical Sciences program (CFDA 47.049) to develop a unifying theoretical framework for membrane fusion processes in biology. The two-year project beginning August 1, 2022 aims to identify common physical principles that govern diverse fusion events such as viral invasion, neuron communication, fertilization, muscle formation, and intracellular trafficking. The...
- The National Institute of General Medical Sciences awarded the University of Virginia $444,125 on July 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the molecular mechanisms underpinning the formation and function of multinucleated cell types, including foreign body giant cells, syncytiotrophoblasts, myofibers, and osteoclasts. The research employs induced pluripotent stem cell modeling to resolve the role of syncytin 1 in multinucleation...
- The National Institute of General Medical Sciences awarded the University of Wyoming $123,687 on March 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on cell fusion and gene expression in the C. elegans epidermis. The research uses the C. elegans epidermal syncytium as an in vivo model system to uncover fundamental mechanisms of multinucleate cell formation and function. The work combines single-nucleus genomics, advanced microscopy, and...
- The National Institute of General Medical Sciences awarded Sanford Burnham Prebys Medical Discovery Institute $2,903,176 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the molecular mechanisms of nuclear pore complex formation. The project, titled "Molecular Basis of Nuclear Pore Formation," will define regulatory principles governing nuclear pore biogenesis in mammalian cells. The research addresses how alterations in...
- This National Science Foundation (NSF) Project Grant, under the Biological Sciences program (CFDA 47.074), was awarded to Stetson University, Inc. in the amount of $502,998 with a period of performance from August 1, 2023 to July 31, 2026. The project aims to investigate the molecular mechanisms of fungal cell fusion, using the yeast Saccharomyces cerevisiae as a model system. Specifically, the research will focus on identifying novel regulators of cell wall degradation and plasma membrane...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Icahn School of Medicine at Mount Sinai $100,228 on November 16, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate mechanosensation in fibro-adipogenic progenitors during skeletal muscle regeneration. The project will elucidate how muscle-resident mesenchymal stromal cells sense mechanical changes in their environment through...
CSHL 2026 CONFERENCE ON CELL AND MEMBRANE FUSION - PROJECT SUMMARY THIS APPLICATION SEEKS PARTIAL SUPPORT FOR THE SECOND COLD SPRING HARBOR MEETING ON CELL & MEMBRANE FUSION , TO BE HELD NOVEMBER 11-14, 2026 AT COLD SPRING HARBOR LABORATORY, NEW YORK. THIS IS THE ONLY CONFERENCE THAT BRINGS TOGETHER RESEARCHERS STUDYING CELL-CELL FUSION, VIRUS-CELL FUSION, AND INTRACELLULAR FUSION IN A SINGLE VENUE, FOSTERING CROSS-FERTILIZATION OF IDEAS ACROSS TRADITIONALLY SEPARATE FIELDS. CELL AND MEMBRANE FUSION EVENTS ARE FUNDAMENTAL TO ALL LIVING ORGANISMS AND PARTICULARLY CRITICAL FOR MUSCLE DEVELOPMENT AND REGENERATION, OSTEOCLAST FUNCTION IN BONE REMODELING, FERTILIZATION, VIRAL INFECTION, AND ORGANELLE BIOGENESIS. FAILURES IN FUSION LEAD TO CONGENITAL MYOPATHY, OSTEOPOROSIS, INFERTILITY, IMMUNE DEFICIENCY, AND SYNAPTIC TRANSMISSION DEFECTS. WE EXPECT APPROXIMATELY 150 ATTENDEES FROM AROUND THE WORLD, OF WHOM ~50% ARE EXPECTED TO BE FROM INTERNATIONAL INSTITUTIONS AND ~60% JUNIOR RESEARCHERS. THE OVERALL OBJECTIVES INCLUDE: 1) TO PROVIDE COMPREHENSIVE ANALYSIS OF RECENT DISCOVERIES IN MEMBRANE FUSION MECHANISMS; 2) TO FOSTER EXCHANGE BETWEEN BIOPHYSICISTS, STRUCTURAL BIOLOGISTS, VIROLOGISTS, AND CELL BIOLOGISTS WHO RARELY INTERACT AT DISCIPLINE-SPECIFIC MEETINGS; AND 3) TO PROVIDE OPPORTUNITIES FOR JUNIOR INVESTIGATORS TO PRESENT THEIR WORK. OUR KEYNOTE SPEAKERS ARE PROF. REINHARD JAHN (MPI GOTTINGEN) AND PROF. GIA VOELTZ (HHMI, UNIVERSITY OF COLORADO BOULDER). SIX PLENARY SESSIONS WILL PRESENT ~50 SPEAKERS (14 CONFIRMED INVITED SPEAKERS AND ~36 SELECTED FROM ABSTRACTS). SESSION TOPICS INCLUDE MECHANISMS OF MEMBRANE FUSION, STRUCTURAL BIOLOGY OF FUSOGENS, CELL-CELL FUSION IN DEVELOPMENT AND DISEASE, MEMBRANE REMODELING, FERTILIZATION, AND EMERGING TECHNOLOGIES. THIS MEETING DIRECTLY ADDRESSES NIAMS PRIORITIES BY ACCELERATING UNDERSTANDING OF MUSCLE CELL FUSION ESSENTIAL FOR REGENERATION AND GENE DELIVERY APPROACHES FOR TREATING GENETIC MUSCLE DISORDERS AND OSTEOPOROSIS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $25.0k | 9/2/26 |